Loading
A phase 2 trial of durvalumab in lung cancer, run by M.D. Anderson Cancer Center, now recruiting.
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) is a phase 2, interventional study registered as NCT05632809 by M.D. Anderson Cancer Center, with a registry enrolment figure of 39 participants, started 2023-01-10 and due to reach its primary completion in 2027-12-31. Interventions recorded: NKTR-255; Durvalumab. Conditions listed: Lung Cancer. Primary outcome: Overall survival time distribution. Lung eligibility wording from the registry: "Histologic diagnosis of non-small cell lung cancer". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.